Madrigal Pharmaceuticals presented real-world studies at AASLD 2026 showing that Rezdiffra (resmetirom) significantly improves or stabilizes liver stiffness in up to 93% of patients with metabolic dysfunction-associated steatohepatitis (MASH) after one year. The data also revealed improvements in liver enzymes, liver fat, and cardiometabolic markers, with up to 72% of patients remaining on treatment after one year. These findings confirm Rezdiffra's effectiveness and safety outside clinical trials, supporting its role as a foundational therapy for MASH patients, including those with comorbidities like diabetes and obesity.
Madrigal Pharmaceuticals' Rezdiffra data is context for readers. For those following the health sector, 88 of 150 US health stocks rose and 58 fell today. ADMA Biologics Inc rose 18.32% to USD 12.40 with 100% sell orders, Nuvation Bio Inc fell 7.82% to USD 4.36 with 100% buy orders, and Cronos Group Inc rose 7.12% to USD 3.76 with 98% sell orders, as of Nov 05, 2026 20:51 WIB.
Scout Clean Energy has announced that its 183 MW Nimbus Wind Farm in Carroll County, Arkansas, is now commercially operational after two years of construction. The wind farm, the largest in Arkansas, generates enough electricity to power over 40,000 ...
CRCAM Toulouse 31 announced the publication and filing of its financial information report for the quarter ending September 30, 2026. The report is accessible to the public on the company's website under the regulatory information section for 2026. T...
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
